NEW HAVEN, Conn., Sept. 10 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of acute care antibiotic-resistant infections, today announced that seven posters have been accepted for presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in San Francisco, CA on September 12-15, 2009. Details on these presentations are as follows:
About Rib-X Pharmaceuticals, Inc.
For more information on the Rib-X mission and the pipeline, please visit the Company website at www.rib-x.com.
SOURCE Rib-X Pharmaceuticals, Inc.
CONTACT: Media, Irma Gomez-Dib, FD Life Sciences, +1-212-850-5761,
irma.gomez-dib@fd.com, or Investors, John Capodanno, FD Life Sciences,
+1-212-850-5705, John.capodanno@fd.com
Web site: http://www.rib-x.com/
